More than 90% of people with Down syndrome develop Alzheimer disease but receive little or no treatment for their dementia. Novel biomarkers of ageing and dementia bring new hope to this medically vulnerable population and can also help researchers understand dementia in other populations.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$32.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$189.00 per year
only $15.75 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Rafii, M. S. & Santoro, S. L. Prevalence and severity of Alzheimer disease in individuals with Down syndrome. JAMA Neurol. 76, 142–143 (2019).
Hartley, D. et al. Down syndrome and Alzheimer’s disease: Common pathways, common goals. Alzheimers Dement. 11, 700–709 (2015).
McCarron, M. et al. A prospective 20-year longitudinal follow-up of dementia in persons with Down syndrome. J. Intellect. Disabil. Res. 61, 843–852 (2017).
Fagan, A. M. et al. Comparison of CSF biomarkers in Down syndrome and autosomal dominant Alzheimer’s disease: a cross-sectional study. Lancet Neurol. 20, 615–626 (2021).
Kinnunen, K. M. et al. Presymptomatic atrophy in autosomal dominant Alzheimer’s disease: A serial magnetic resonance imaging study. Alzheimers Dement. 14, 43–53 (2018).
Cole, J. H. et al. Brain-predicted age in Down syndrome is associated with beta amyloid deposition and cognitive decline. Neurobiol. Aging 56, 41–49 (2017).
Ferrari, M. & Stagi, S. Autoimmunity and genetic syndromes: A focus on Down syndrome. Genes 12, 268 (2021).
Gafson, A. R. et al. Neurofilaments: neurobiological foundations for biomarker applications. Brain 143, 1975–1998 (2020).
Carmona-Iragui, M. et al. Diagnostic and prognostic performance and longitudinal changes in plasma neurofilament light chain concentrations in adults with Down syndrome: a cohort study. Lancet Neurol. 20, 605–614 (2021).
Montal, V. et al. Metabolite signature of Alzheimer’s disease in adults with Down syndrome. Ann. Neurol. https://doi.org/10.1002/ana.26178 (2021).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing interests.
Rights and permissions
About this article
Cite this article
Granholm, AC., Ledreux, A. Biomarkers show value of studying dementia in Down syndrome. Nat Rev Neurol 17, 599–600 (2021). https://doi.org/10.1038/s41582-021-00558-w
Published:
Issue date:
DOI: https://doi.org/10.1038/s41582-021-00558-w
